Banco Santander S.A. Trims Stock Position in Novo Nordisk A/S (NYSE:NVO)

Banco Santander S.A. trimmed its stake in Novo Nordisk A/S (NYSE:NVO) by 2.0% in the 3rd quarter, HoldingsChannel reports. The firm owned 68,871 shares of the company’s stock after selling 1,382 shares during the quarter. Banco Santander S.A.’s holdings in Novo Nordisk A/S were worth $8,200,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of NVO. International Assets Investment Management LLC boosted its position in Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after acquiring an additional 1,796,635 shares in the last quarter. DSM Capital Partners LLC lifted its stake in shares of Novo Nordisk A/S by 257,816.0% in the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after purchasing an additional 1,593,303 shares during the period. Mediolanum International Funds Ltd bought a new stake in shares of Novo Nordisk A/S during the third quarter valued at approximately $98,765,000. Price T Rowe Associates Inc. MD grew its stake in Novo Nordisk A/S by 10.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 8,589,222 shares of the company’s stock worth $1,102,857,000 after purchasing an additional 823,036 shares during the period. Finally, Marshall Wace LLP raised its holdings in Novo Nordisk A/S by 34,472.1% in the second quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock worth $98,696,000 after purchasing an additional 689,441 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NVO has been the topic of a number of research reports. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Stock Down 2.4 %

NYSE:NVO opened at $102.77 on Friday. The firm has a 50-day simple moving average of $116.12 and a two-hundred day simple moving average of $128.92. The firm has a market cap of $461.18 billion, a P/E ratio of 33.26, a P/E/G ratio of 1.32 and a beta of 0.42. Novo Nordisk A/S has a fifty-two week low of $94.73 and a fifty-two week high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.